Severe or Disseminated Pulmonary Nocardiosis: What to Do When Empiric Combination Therapy Has Not Worked

This protocol covers the hospitalized immunocompromised patient with severe pulmonary nocardiosis — including disseminated nocardiosis and progressive pulmonary infection — who has not achieved the expected clinical and radiographic response on initial empiric treatment.

Clinical Scenario

Severe pulmonary nocardiosis, including disseminated nocardiosis and progressive pulmonary infection, is characterized by a rapid clinical course from onset to diagnosis. Affected patients are typically immunocompromised and require inpatient management. In this setting, aggressive susceptibility-guided therapy is particularly important.

Prior Therapy — Failure Condition

The preceding line used empiric combination therapy — incorporating agents such as amikacin, imipenem, linezolid, and trimethoprim-sulfamethoxazole — directed at broad Nocardia coverage. This next-line protocol is indicated when that regimen has not produced the required signs of clinical improvement of pulmonary nocardiosis or the expected radiographic response on follow-up chest imaging.

Next-Line Approach (Partial Overview)

Management transitions to susceptibility-guided selection of an alternative active agent; specific agents with in vitro activity against essentially all Nocardia isolates are considered — the complete regimen, selection criteria, and treatment goals are detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciae643

In contrast, patients with severe nocardiosis are typically hospitalized and have a more rapid course from onset to diagnosis.

This is particularly crucial in severe forms of nocardiosis (eg, disseminated or progressive pulmonary infection), where 2 or 3 different agents are typically initiated empirically.

Patients with TMP-SMX toxicity and yet-to-improve severe infection may be better served transitioning to alternative therapy, as patients with severe nocardiosis are underrepresented in the available data.

Linezolid is uniquely susceptible in vitro to essentially all Nocardia isolates.

Patients with pulmonary or CNS disease should undergo follow-up chest or brain imaging, respectively, to evaluate for response to treatment.

View source ↗